Dr. Marios Giannakis, MD

Dr. Giannakis practices at Dana-Farber Cancer Institute in Boston, Massachusetts, part of Dana-Farber Cancer Institute.

Dr. Giannakis' NPI, 1417185729, was assigned on June 25, 2009. Dr. Giannakis graduated from WashU Medicine in 2009. Dr. Giannakis holds Massachusetts license 246728.

Dr. Giannakis' primary practice is Dana-Farber Cancer Institute, at 450 Brookline Avenue, Boston, MA 02115.

Dr. Giannakis' primary practice is Dana-Farber Cancer Institute in Boston, Massachusetts, part of Dana-Farber Cancer Institute. Dr. Giannakis is also affiliated with Brigham and Women's Hospital. The medical group on file is Binney Medical Group.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Giannakis practices, 2 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Giannakis' primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Giannakis is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Giannakis' licenses on file in 2 states: Massachusetts and California.

Dmand AI lists colorectal cancer among the conditions Dr. Giannakis treats.

CMS data shows 29 Medicare services from Dr. Giannakis across 1 procedure code in 2024, all of them office visits, for 23 Medicare patients. Medicare paid $3,324 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 23 Medicare patients who saw Dr. Giannakis in 2024. The largest group is 65 to 74, with 11 patients. 74% of them have high blood pressure, and 65% have high cholesterol. Their average risk score is 2.35, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Giannakis' median patient age at 64, with 43% women.

In 2024, Dr. Giannakis wrote 40 Medicare Part D claims for 12 patients. 75% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $14,856 in total drug cost. In 2020, CMS named 24 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Giannakis for performance year 2024, reported as part of a group. Dr. Giannakis accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 174 papers to Dr. Giannakis, published from 2006 to 2025. 2020 was the busiest year, with 23. The most frequent topics are Colorectal Neoplasms, Microsatellite Instability and Biomarkers, Tumor. Dr. Giannakis has published most often in Cancer Immunol Res. Dr. Giannakis' most frequent co-authors are Charles Stewart Fuchs, MD, MPH, Kimmie Ng, MD and David Alan Drew, MD.

Dmand AI links Dr. Giannakis to 4 clinical trials, 2 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Colorectal Neoplasms, Colonic Neoplasms and Esophageal Squamous Cell Carcinoma. Massachusetts General Hospital sponsors the most, 2.

CMS Open Payments shows 7 general payments to Dr. Giannakis from 3 drug and device companies from 2018 to 2023. Grants make up the largest share, 96% of the total. Genentech, Inc. paid the most, $133,334. It also lists 1 research payment totaling $143 in 2018.

Dr. Giannakis graduated from WashU Medicine in 2009.

Dr. Giannakis is in network with 13 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.